Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
Publication
, Conference
Sekeres, MA; Othus, M; List, AF; Odenike, O; Stone, RM; Gore, SD; Litzow, MR; Buckstein, R; Fang, M; Roulston, D; Bloomfield, CD; Zhang, Y ...
Published in: BLOOD
December 3, 2015
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., … Erba, H. P. (2015). Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Sekeres, Mikkael A., Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, et al. “Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, et al. Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. In: BLOOD. AMER SOC HEMATOLOGY; 2015.
Sekeres, Mikkael A., et al. “Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Appelbaum FR, Erba HP. Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. BLOOD. AMER SOC HEMATOLOGY; 2015.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology